At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 151 enrolled
Drug / intervention
AGN-199201 ophthalmic solution +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients With Presbyopia
In Brief
A Phase 2 clinical trial evaluating AGN-199201 ophthalmic solution, AGN-190584 ophthalmic solution, and 2 other interventions for Presbyopia. Completed, enrolled 151 participants across 25 sites.
Detailed Summary
This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201 and AGN-190584 in participants with presbyopia (inability to focus on items close-up).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartMay 2016
Primary CompletionOct 2017
TodayJul 2026
First PostedMay 23, 2016
Enrollment StartMay 26, 2016
Primary CompletionOct 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.1 years ago
Interventions
AGN-199201 ophthalmic solutiondrug
1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
AGN-190584 ophthalmic solutiondrug
1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
AGN-199201 Vehicledrug
Vehicle to AGN-199201
AGN-190584 Vehicledrug
Vehicle to AGN-190584